The BEST Health Supplement Affiliate Program 💰 Make 30%

8 Alternative of Amazon Affiliate for Beginners

When I was young, I loved getting hand-me-downs.
My cousins were all older than me, so every once in a while they’d bring a huge bag of hardly-worn clothes that I could pick and choose from. While the clothes were a perfect fit for me, they were no longer useful to my cousins, since they’d grown out of them.
So what do hand-me-down clothes have to do with alternatives to Amazon Associates?
Well, just like my cousins decided to get rid of clothes that were no longer useful to them, many people have decided to leave the Amazon Associates program recently because they’re not finding it as useful anymore. They’ve outgrown it, and they’re ready to look for more niche affiliate programs with higher-ticket items and higher commission rates.
Of course, there are still many affiliates who think this program is the perfect fit for them, just like those hand-me-downs were the perfect fit for me. Many of these affiliates are beginners looking for an easy start, fast acceptance and a wide range of products to experiment with.
So, how do you know if it’s time for you to look for alternatives to Amazon Associates? And what kind of alternatives might you find?
That’s what we’re going to learn today! Let’s check out some of the top niche affiliate programs that can help you replace Amazon Associates, as well as why you should consider them. You can also consult our reviews of the top 5 affiliate networks here, for even more options. Why Should Affiliates Find an Alternative to Amazon?
We all know about the changes in the Amazon Associates program that took place back in March. Amazon completely restructured its commissions, defining rates by category instead of by the amount sold.
This was an especially hard hit for big affiliates who got stuck in low-paying categories.
For example, let’s say you have an affiliate marketing website that was referring more than 3131 sales per month in the category of PCs and PC parts. Before March, you would’ve been earning an 8.5% commission for every sale. But now, you would only be earning 2.5%.
Many affiliates still find Amazon Associates to be worthwhile for them and their affiliate marketing business. Others, however, are stuck in categories such as health, automotive, sports, toys and tech, and thus getting a commission rate of 5% or less.
If this is true of your affiliate marketing business, you might decide it’s time to look for alternatives to Amazon Associates. So, where can you turn? 8 Niche Affiliate Programs That Are Alternatives to Amazon Associates
Amazon is a huge conglomerate of a company that quite literally sells everything. It’s internationally known and used, and it’s still a valuable resource for many affiliates. There’s not a single program that can fully replace Amazon.
That being said, if you’re stuck in a low-paying category in Amazon Associates—or just looking for more specific products that Amazon doesn’t have—reaching out to niche affiliate programs that fit your business is a great way to recover!
Going through the low-commission categories we mentioned above, here are some fantastic niche affiliate programs that can help you replace Amazon Associates:
Multi Product 1. Crovals.com Online Business
Visit Affiliate Program
This website have brand a wide range of great items & all kind of category. who love to learn! This is mainly an multiple resource eCommerce store. you can affiliate any products if you want to sell.
Users report earning 20% commissions on all sales, They will give you $100 bonus for every 100 products sold with a commission. which is double Amazon’s commission rates. Crovals affiliate program is run through GoldenOffers and features 15-day tracking cookies.
  1. TigerDirect Affiliate Program
This company sells everything that a PC affiliate could ever dream of! If you’re looking to refer sales for PCs, laptops or any of their pieces, you’ll be happy with TigerDirect.
The commissions for TigerDirect are 3% compared to Amazon’s 2.5%. You’ll have to decide if this increase in percentage is worthwhile for your business.
  1. Microsoft Affiliate Program
As a well-known tech company, Microsoft has plenty to offer affiliates. You can earn up to 10% depending on the items you choose to promote.
Microsoft affiliates can promote the tech that Microsoft produces. The best commissions are found in software (such as Office), music downloads, TV shows, apps and games within the Windows Store.
Gaming affiliates can also promote the Xbox game consoles and games, but these only offer a 2% commission. However, this is still an improvement from Amazon’s 1% commission rate for video game consoles.
Health
  1. The Vitamin Shoppe Affiliate Program
The health and personal care category in Amazon Associates was demoted to a mere 4.5% commission rate in March.
If you’re looking to improve your commissions with a well-known health brand, look no further than The Vitamin Shoppe. With more than 25,000 products to promote, affiliates will always have plenty of material!
More than that, The Vitamin Shoppe offers 9% commissions, which is a huge improvement from Amazon. This affiliate program is run through CJ Affiliates.
Automotive 5. AutoZone Affiliate Program
Another CJ Affiliate program, this automotive company offers an 8% base commission. More than that, high-volume affiliates will get bonuses for their hard work!
AutoZone is a trusted brand in the automotive world. For affiliates, joining this program means making almost double Amazon’s automotive commission rate, as well as having access to 45-day tracking cookies! You’ll also have access to a dedicated affiliate manager, in case you have any questions.
  1. Advanced Auto Parts Affiliate Program
This top US automotive brand is another great option for automotive affiliate marketers. You’ll be able to earn 8% commissions on all your referred sales.
Also run through CJ Affiliate, the Advanced Auto Parts affiliate program allows you to promote deals to customers like free shipping on orders over $75 and more!
Sports and Outdoors 7. Columbia Affiliate Program
While sports and outdoors both earn less than 5% commissions on Amazon, Columbia offers affiliates up to 10% commissions!
As a well-known outdoor brand, Columbia is a great option for affiliate marketers in this category. It features 21-day tracking cookies, as well as access to a dedicated affiliate manager. This program is also run through CJ Affiliates.
  1. Nike Affiliate Program
This program offers 11% commissions on orders that average $100. It also features 30-day tracking cookies, and plenty of creative materials to place on your website.
Another cool feature of this program: If you want to run a promotion or competition, Nike offers gifts that you can give out to your readers!
The only downside of the Nike affiliate program is that it’s only available in certain countries, and the US isn’t currently one of those countries. However, any affiliates who are based in the UK or Europe will have no problem!
As we mentioned above, there’s no single program that can completely replace Amazon Associates. This incredible company is one of the largest online retailers currently running, and there simply isn’t another affiliate program that gets you the range of products and categories that Amazon does.
That being said, the niche alternatives to Amazon Associates that we’ve discussed above are fantastic options for those who a stuck in low-commission categories.
Of course, each affiliate marketer will have to decide whether switching from Amazon to another affiliate program is the right move for their business. Or, maybe you’ll find that using the aforementioned niche affiliate programs together with Amazon Associates works better for you!
Whatever you decide, these niche alternatives to Amazon Associates are a great place to start when you’re looking to expand your affiliate earnings.
submitted by catlovertshirt_com to alternative_affiliate [link] [comments]

2020 Psychedelic Industry Insights Report

By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best Decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Due to poor understanding of mechanisms, complex clinical trials and systematic side effects, Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to reduce or cut their Neuro programs in the last decades. Recently, engagement is exploding with new clinical legislature supporting Neuro and the recent approval of 3 potentially blockbuster Neuro drugs in the last 2 years,
Q2 2019 saw a record of over $320M in investment into Neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals including PayPal founder Peter Thiel funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. In 2019 Atai Lifesciences acquired Perception Neuroscience and GABA Therapeutics for their next generation tranquillisers. Last week, Atai also acquired NeuroNasal, a non-psychedelic company creating a concussion nasal spray. In partnership with pharma, Atai's recent launch of EntheogeniX, an AI based psychedelic drug discovery platform, shows that Atai is serious about making investments into the fundamental research required to continue being an industry leader in the long-term. It is rumoured that Atai has made a number of cash investments recently, so new partnerships and acquisitions should be expected in the next months.
The collapse of investable cannabis opportunities are driving investors comfortable in stigmatised industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelics Industry?
Historically, the psychedelics industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $220M+ worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-25 early companies in the range of $2.5-10M each. The $220M+ worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelics Market?
The psychedelics market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B+
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight:
Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $100M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, $15M+, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $12M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh Pharmaceuticals - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen Labs - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $8M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020
Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $35M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster Neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. This is showing addiction can be treated with new mechanisms that are much more low level than replacing the drug in the receptor. Academic data unequivocally shows that Ibogaine is 95% successful in terminating acute opioid withdrawal symptoms permanently from a single dosage. Limited data from long-term Ibogaine for opioid addiction trials show 50% success rates in terminating addiction in the 6 month period with a single dosage, more than 10X higher than the generous 5% success rate of other approaches in the 6 month period. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched crack again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards. Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B+ in value yearly. Ibogaine's very reasonable projected 5% penetration into the opioid dependence market in the next 10 years will bring $9.6B+ in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialisation of the current late stage clinical trials which are in progress.
Highlight:
Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved for the general market. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drug Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location. Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next few years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of Ibogaine to endangered status in 2019 and no synthetic GMP producers - the Ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk. At the current moment, around 5-10 psychedelic investment funds are forming in the range of $10-50M each, including the Cannacord Genuity backed Entheos and the $20M psychedelic quant fund Tabula Rasa Ventures.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8+ trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $0.75 through automation, mushroom protein becomes significantly more commercially competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective and produces a life threatening condition called Precipitated Withdrawal. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200X microdoses. When dosages increase past the perceptual threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for neural growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptor system. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh Pharmaceuticals, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic, fueled secondarily by histories cheapest and most available synthetic drugs. With Johnson and Johnson settling with two counties in Ohio, projections have placed the total at $100B+ in fines for the opioid crisis in the next few years. State jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterised by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
submitted by mindovermatterlondon to investing [link] [comments]

Day 18 Clean and Off Tia Sodium 15 gpd habit for 1 year. How I did it and how you can too

Hey everyone, like most of us, i started taking tia sodium with the intention of never letting it escalate to addiction and physical dependence. To keep this part of the story short, my use rapidly increased from 100mg a few times a day to 12-15 gpd. I maintained that dose for ~ 1 year but it was killing me financially, and literally i later found out. I started reaching out to addiction specialists (none of which have ever heard of Tia) and they had no advice other than admit myself to a detox center / the ER. They said from their research that the acute WD hit so fast and hard due to the short half life it would be the safest and most effective way to do it. I live in Northern NJ, near NYC so i figured some place around here had to have experience with this. After many many calls and failed attempts i found a detox center that had successfully detoxed 1 individual off of Tia with little issue. They said they would treat me even though i would test clean for all substances. I had previously come clean to my gf who is also a doctor and she agreed this would be the best decision. We packed up my stuff, i took the remainder of my tia over that night and in the morning i took 1 final (massive) dose and she drove me to the detox center.
I was admitted around 10am. They took my initial assessment and some blood work and sent me up to the detox floor. I was under the impression they were going to just watch me and make sure i didnt die or something, but they actually developed a full medical detox program with medication to make the acute WD as painless as possible. The short version is they developed a short 6 day Bupenephorine (Subutex) taper. This form does not contain naloxone. I had to wait 24 hours before taking the Bup. At about 12-15 hours i was in full blown WD, however they loaded me up on muscle relaxers, anxiety medication (multiple forms), Gaba and Clonidine and a few other things. It was still very uncomfortable but it was bearable. I had WD a few times when a package ran late so i know how bad it can be. At the 24 hour mark, they gave me 8 mg of Bup. Yes i know this is not enough to kill all WD and it did not. I felt almost no relief from this first dose. The next day they gave me 6 mg and I was still felling pretty shitty but functional. The next few days they gave me 4 mg and by day 4 i noticed i was felling pretty good. I could eat and was sleeping for 4-6 hours at night. They also gave sleeping medication (not sure if that helped at all or if it was just the Bup). At that point i started attending the educational sessions they had through out the day on addiction and what not. It was pretty informative. Days 6 and 7 they gave me 2mg of Bup per day. Those days i felt ~75% ok. Throughout the entire time, all the other medication i listed above (except the anxiety meds, no need to start a benzo addiction there) were continued as well including vitamins to replenish what was lost through tia addiction. It felt comforting to be there around other people that were struggling. They also monitored your Blood Pressure, Heart Rate, and Oxygen levels multiple times per day/night. There was registered nurses there 24/7, a doctor who came in daily, and immediate ambulance access in case of emergency. You also met with a councilor everyday to talk about your addiction and recovery. I left the center clean from tia for 7 days straight with no intention of ever going back to tia. Another option would be to do the 7 day detox, followed by 15-30 days of rehab. I chose not to do that because i couldnt get that much time off work.
What i later learned is that Bup has a very long half life, so basically the first 3 days the Bup levels in my blood were still building then slowly ramped down as the dosage lowered. Days 8-10 out of the center were pretty terrible as the Bup wore off, but nothing compared to acute WD. I returned to work and everything was ok. Mostly the Restlessness, 0 energy or motivation, hot/cold flashes, freezing all the time, depression, anxiety, extreme muscle pain and 0 sleep. However, at day 11 it was like a light switch flipped. My interests/confidence started coming back, legs started making improvements, sensitivity to temperature decreased, and i started sleeping. Every day since has been an improvement. Last night i slept 7 full hours and i feel ~90%. The only remaining issues are some minor chills, and ive been sweating alot. I think this is from my body readjusting to normalcy and testosterone levels returning. One final thing to mention, when my blood work came back i was informed my kidneys were basically none functional. This explained the extreme sweating and lack of urine while i was using. Day 5 in treatment they took my blood work again, and everything had returned to normal (including kidney function). Its crazy how tia can hurt us so bad while using and how quickly we adjust once clean. Also, this is only my experience so take it for what it is. I know everyones experience can be different.
Sorry for the long post but i felt as if i would never find a way out, and now that im 18 days clean i have never been happier and i wanted to tell how i managed to do it. I tried tapering and CT on my own many times, all which failed miserably. Im not saying tapering isnt possible, it just wasnt for me. I give extreme credit to anyone that has successfully or is successfully tapering at the moment, your will power is much stronger than mine.
Also btw, i am not affiliated with this detox center or anything but i asked them if i could throw their name out in a reddit forum to help others. They said of course. Probably so they can get some business and to help others. If you have insurance, they will send an uber to your house and set up/pay for your method of travel (car, train, plane, whatever it takes to get you there based on your geographical location). I dont know the rules of reddit but dm me if your interested in knowing the name. Also, you can always reach out to centers near you and explain this and hopefully they will admit you. I know alot of places wont if you pee clean.
Anyways, thanks for reading and good luck to everyone
submitted by stuckinahole561 to QuittingTianeptine [link] [comments]

2020 Psychedelic Industry Insights Report - ThinkMyco

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[email protected]
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.

Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to shroomstocks [link] [comments]

30 AFFILIATE PROGRAMS THAT PAY COMMISSIONS FOR LIFE!

In all associate programs, affiliate marketers get paid to promote affiliate products. This business has become popular because affiliates don't have to own or keep stock in order for them to make sales. All they have to do is direct traffic to a vendor's webpage. And if a potential customer makes a purchase the affiliate attracts a commission. Commissions in this type of business can be as high as 75% on front-end products.
It’s possible for the affiliate marketer to make money repeatedly with 1 sale. It’s also possible for the affiliate to continue making money from the same for as long as the prospect stays a client.
This is one of the reasons that drive many successful affiliate marketers to focus their efforts on programs that offer recurring affiliate marketing income. When they promote services or digital products such as web hosting, membership sites, and autoresponders, they earn a commission every month, for as long as the customer keeps the service or remains a member. Once they make a few more sales and add more customers to their list. The commissions they earn add-up to a nice monthly income. Because affiliate marketing is very cost-effective, the income is not only recurring but a large portion of it is profit.
Without a doubt, each person will not remain a lifelong customer. But if you're promoting good products and services to the right group of people. Chances are, a good number of them will stick with those products and services for months or years after the initial sale. In a year's time, you'll make twelve times more money from the same sale compared to a once-off sale.
There's some sort of membership or ongoing service that will appeal to just about any niche. And if you can't find one for your niche market, consumables are the next best thing. Vitamins, pet food and other products that we have to buy again when we run out, offer the potential for you to make money repeatedly with 1 sale, if the customers are loyal.
6 Types Of Online Products That Pay Repeatedly
I have given a list below of the services that you can use to start building your recurring affiliate marketing income today. However, you have to accept the responsibility of reading the affiliate agreement carefully to ensure that you can attract recurring income from any of the listed programs or those of your choice.
I am not going to offer any explanation on each affiliate program. I encourage to go over to their sites and check it out for yourself.

1. Web Hosting Affiliate Programs
I would like to begin with Web Hosting affiliate programs because everyone who is serious about building an online business will eventually use these services. Some may begin with free hosting in popular websites such as Wordpress(http://wordpress.com), Blogger or Wix. But if the individual really wants to take it to the next level, they must pay for web hosting space.
Here are some of the web hosting affiliate programs that can help you build a recurring affiliate marketing income.

2. Email Marketing/Autoresponder Affiliate Programs
Second on the list is email marketing service providers. I can never overemphasize the importance of email marketing in any online business. If you are just getting started, you need to understand the power of email marketing and harness it!
Here is a list of autoresponders that offer affiliate programs that can generate you a recurring affiliate marketing income.

3. E-commerce Affiliate Programs
The next list refers to services that allow online entrepreneurs create and manage online stores. Some of these service providers also offer shopping cart solutions and drop shipping services.

4. Online Academy Affiliate Programs
These are affiliate programs for Online Institutions that offer training. I could only find one that offers recurring income. It is ClickBank University.
5. WordPress Add-ons Affiliate Programs
By add-ons, I am referring to Themes and Plugins that are used to enhance any Wordpress site. It is no secret that most of the top flying online entrepreneurs like to stand out from the crowd.
They often achieve this by purchasing add-ons. Also, they choose to use upgraded plugins to enhance the outcome or performance of their WP sites.

6. Online Marketing Services
The list below includes affiliate programs for all service providers that intend to help online entrepreneurs increase their traffic and grow sales through various methods including social media marketing.

submitted by OnlineMarula1 to Affiliatemarketing [link] [comments]

Scientology/Narconon Creates Fake Website Based on Reachingforthetippingpoint.net

Narconon created this site:
https://pastthetippingpoint.net/ which lies about what Narconon really is, a Scientology scam
Narconon created the fake site in hopes that their website would come up on searches when people where looking for the truth about Narconon.
The actual site that shows the danger of Narconon:
http://www.reachingforthetippingpoint.net/
(The fact a rehab center would do this should be one clue that Narconon is NOT a rehab center.)
This is the first page on the real site:
What is Narconon? Why should I be concerned? Have you attended a Narconon program? Please consider doing the Narconon Survey here: http://reachingforthetippingpoint.net/narcononsurvey/
Narconon has been receiving some bad press lately. Most recently, there have been news stories about 3 deaths within a 7 month period at Narconon Arrowhead in Oklahoma: on the forum, read Narconon Oklahoma Multiple Deaths, and the death of Patrick W. Desmond at Narconon of Georgia: on the forum, read The Desmond Family v. Narconon of Georgia, Narconon International, et al.
Court filings from the Patrick Desmond case can be viewed and downloaded here: Desmond v. Narconon.
Unfortunately, those are not the only deaths. Deaths have occured throughout Narconon's history. There is an incomplete list in the thread Narconon Deaths.
You would think that, if something as serious as death continues to occur with a particular rehab method, the methods should be changed to incorporate safer and more modern practices. Narconon does not do this, but instead has the attitude that their program is authoritative, and if problems occur, the problem is with the client, not with Narconon. Nothing could be further from the truth.
More About Narconon Narconon is a controversial drug rehabilitation program based on the ideas of L. Ron Hubbard, a science fiction writer and founder of the Church of Scientology. Many people believe that Narconon is simply a front group for Scientology with the purpose of making money and recruiting new members for Scientology. Although Narconon is recognized as a non-profit 501(c) (3) organization, it does charge for services.
For information about other Scientology-run front groups, visit our What is Scientology? page.
Narconon’s ties to Scientology are not disclosed or readily available to its clients who are making a decision on treatment for drug addiction at a vulnerable time in their lives. Additionally, Narconon’s doctrines and organization are nearly identical to Scientology’s.
Narconon has an aggressive web presence and registers web sites with misleading names, which are presented as objective reviews of drug rehab centers but are actually used as advertisements for Narconon.
When many people hear the name "Narconon," they think it is another name for Narcotics Anonymous. It isn't.
The Narcotics Anonymous (NA) website clearly shows that NA does not charge for services, does not provide residential facilities or clinics, does not provide vocational, legal, financial, psychiatric, or medical services, and is not affiliated with other organizations. Facts about NA can be found here: http://www.na.org/?ID=Home-basicinfo The Narcotics Anonymous (NA) website uses factual and informative language: http://www.na.org/, and most of their publications are available for free: http://www.na.org/?ID=ips-eng-index Narconon, on the other hand, uses a highly structured, one-size-fits-all program, which parallels the training sold to members of Scientology: http://www.narconon.org/drug-rehab/narconon-drug-rehabilitation-program.html The Narconon website uses emotionally charged, marketing-style language: http://www.narconon.org/. No publications are available for free: http://www.narconon.org/bookstore/. Find out more about the relationship between Narconon and Scientology here: http://www.cs.cmu.edu/~dst/Narconon/nn-scn.htm Narconon has an aggressive web presence, including a large number of referral sites that present themselves as unbiased referrals who will refer you to the best rehab for your specific needs, but somehow, Narconon turns out to be "the best" for everyone's needs who contacts them. There are also generic-appearing blogs, which are intended to direct people to Narconon. Phone numbers tie to specific people, known as Field Staff Members (FSMs, a Scientology term), who refer visitors to Narconon, and provide them with a commission of 5% to 10% of the total fees paid to Narconon. There are screenshots from a video teaching how to set up one of these blogs here: http://forum.reachingforthetippingpoint.net/index.php/topic,368.msg2196.html#msg2196 What else is wrong with Narconon? Hubbard, who co-founded Narconon in 1966, had no medical qualifications and was ignorant of basic medical facts. Despite advances in research on treatment of alcoholism and substance abuse, the Narconon program remains unchanged. Narconon uses unproven techniques and potentially dangerous levels of vitamins far beyond those considered safe by the FDA. For instance, Narconon prescribes niacin in dosages reaching 5,000 mgs to their clients. The daily recommended intake by the FDA is 20 milligrams. When doses this high are given, serious side effects can occur. These side effects include liver problems, gout, stomach ulcers, loss of vision, high blood sugar, irregular heart rate and other problems. These side effects are particularly concerning for patients who may be more vulnerable to liver damage as a result of alcoholism or drug addiction.
Learn more about L. Ron Hubbard's lack of qualifications here: http://www.cs.cmu.edu/~dst/Narconon/science.htm There is a list of Narconon's unsafe practices, including a list of the vitamins and minerals used in the program, here: http://www.cs.cmu.edu/~dst/Narconon/detox.htm The Food and Drug Administration's Recommended Daily Values can be found here: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/FoodLabelingGuide/ucm064928.htm What about Narconon staff? Narconon often employs former clients who have recently completed the program. This is a huge risk for newly recovering clients. It is not unusual for former alcoholics or addicts to enter the counseling field. However, this is usually after an established period of sobriety and formal training or certification as a substance abuse counselor has been completed. This is not the case at Narconon. In addition, Narconon of Georgia was recently cited for inappropriate monitoring of drug screens on clients and employees.
What kind of training do Narconon staff members have? Where does the staff of Narconon come from? http://www.cs.cmu.edu/~dst/Narconon/staff.htm The Board of Mental Health of the State of Oklahoma investigated Narconon for certification as a drug and treatment facility in 1992 and found that Narconon hires former students (as clients are called) immediately upon graduation, as well as other alarming observations: http://www.xenu.net/archive/oca/narconon/91report.html An article from March 21, 2010, entitled "Intoxicated by Narconon" was published in a Canadian newspaper, "le Soleil." Here is the original article in French: http://www.cyberpresse.ca/le-soleil/actualites/societe/201003/20/01-4262723-intoxique-par-leglise-de-scientologie.php. Here is an English translation: http://www.forum.exscn.net/showthread.php?t=17001. This testimony from a former staff member states that many Narconon graduates go on to work at the facility due to pressure from current staff: http://www.anti-scientologie.ch/narconon-testimony.htm Criminon Second Chance, and other Narconon affiliates Criminon Second Chance is a prison-based version of Narconon that seeks public funding for the program. Criminon Second Chance was evicted from Alberqueue, New Mexico after breaking an agreement with the City. They were allowed to operate a facility in an old jail to house nonviolent male inmates with a history of substance abuse problems, but were found to be housing violent offenders and women inmates also. After being given a notice to comply with the agreement, they left secretively in the middle of the night with 19 inmates in an old bus, leaving their rent and utility bills unpaid. Scientology promotes this front organization without revealing the connection to Narconon or Scientology. Read more about Criminon Second Chance here: http://forum.reachingforthetippingpoint.net/index.php/page,Criminon.html
In order to avoid the bad reputation that is developing from public exposure of the Narconon program, some "Sauna Detox" programs are using names which do not include "Narconon", but use the same L. Ron Hubbard and Scientology techniques and course material for the program. For addictions that require it, some Narconon-affiliated programs use a medical detox procedure first, and then refer people on to a more standard Narconon-style sauna detox with Scientology-based coursework. Some of these include (but are not limited to) generic names like New Life and First Step, Pur Detox, and Best Drug Rehab; and more specific sounding names like Sunshine Summit Lodge, Huntington Harbor House, Novus Detox, and Suncoast Rehab Center.
Finding a good, legitimate rehab facility If you are seeking a drug rehab facility, the most important thing you can do is to research the facility by name. Once you have narrowed down to a few that you are considering, check with the agency in the state or country that licenses drug rehab facilities about prior violations and license revocations for the specific facilities. Ask for specifics about the program - exactly what the program entails, how long it will last, who the program director is and what their qualifications are, who the medical director is, what the policy is with regard to employment of counselors and other staff members, and ask to tour the facility first before signing anything. Ask advice on some of the discussion forums that specialize in drug and alcohol rehab. Ask advice from people you know. The main thing you want to do is avoid being in a hurry and not thoroughly researching the facility you choose. There are good programs out there - they may just not be the first ones you find when you search the web.
Are you still considering going to Narconon? Before you decide, please read about the experiences of someone who's been there: My Narconon Story, by Sekh:
SEKH'S EXPERIENCE AT NARCONON My Narconon Story, by Sekh Have you attended a Narconon program? Please consider doing the Narconon Survey here: http://reachingforthetippingpoint.net/narcononsurvey/
Would you like to discuss Narconon? Do it in the Narconon section of our forum: Narconon and related groups here: http://forum.reachingforthetippingpoint.net/index.php/board,46.0.html
My story.
We go back to 1990, I was 28, a single mother, with two children of 8 and 2 years old, and a huge heroin addiction. Things weren't looking good, to say the least. I had tried rehab before, and it somehow never worked out, so I kinda gave up on the thought of ever getting clean. Tried to care for the kids as good as I could, but I knew things had to change or I would lose them. Just didn't know how to make that work.
Then, out of nowhere, my ex-husband called me. He was also a heavy drug-user. He told me he was in this place, Narconon, to get rid of the drugs, and it was so different from any other rehab program, it was just great. Maybe I could find help there too.
So we talked a bit, and I told him I would think about it, and he said he would call me again soon, to tell me how he was doing. Though we were divorced, we always remained friends, and I was glad he found a place where people could help him. He called me several times over the next week, and I started thinking about my life, and about the opportunity to get clean, and that maybe I should go there too, so I asked to talk to a staff-member.
No problem, this very friendly guy took over the phone and listened to my story. He really seemed to understand what I was saying, and he really started me thinking about hope. Hope is a mighty big thing when you're addicted, because usually there doesn't seem to be any.
I only had two questions. The first: Could I take my little daughter with me? He said that it wasn't good for her to be with me while I was in detox, but afterwards she could come and I could finish the program with her there. That sounded very sensible. My son had to go to school, so he could not come with me anyway, but he could stay with my parents.
My second question was about scientology. I knew there was some link between Narconon and the Church of Scientology. Had he denied that, I would have exposed him as a liar, but he gave me my first taste of "acceptable truth" right there on the phone. He said:" Our philosophy was developed by L. Ron Hubbard, who also founded Church of Scientology. So Narconon uses some scientology techniques, but is a totally independent foundation, and there are no ties to the church. People from every faith are welcome, we are strictly neutral about religion."
All very reasonable, quite believable. He put my ex back on the line and let him finish the job of luring me in. At the end of the conversation I promised to come the next day. At that moment I believed that I was given a great opportunity to turn my life around.
That night I arranged the staying of my children with their grandparents, and a neighbor to feed my pets and take care of my plants and I packed a suitcase with some clothes and other necessary stuff. Early the following morning I took the train to Zutphen, about one hour from my hometown.
From the station I called Narconon an they sent a car to pick me up. Great service. To my surprise my ex-husband, let's call him Bob, accompanied the driver, and after some hugging, crying and kissing we took of to the Narconon premises.
I wasn't quite sure what to expect; something like a hospital, or maybe a kind of farm-like setting, but it turned out to be a villa in the center of town, built somewhere between the two world wars and in a poor state of maintenance. The first thing that happened was a thorough check of my suitcase, looking for drugs, alcohol and medications. Then a female staff-member asked me to take my clothes of, so she could check my body for “contraband”.
Remember, I hadn't yet agreed to follow the program, hadn't even had an intake-procedure of some kind. I tried to rationalize this by saying to myself that they had the safety of their patients to concern and didn't protest, not even when they took my books, my personal papers,my jewelery and money and even some cosmetic articles away “for storage”. After this visitation I was introduced to the staff, an American lady named Joanna who was the director and some Dutch volunteers who were ex-clients themselves.
Joanna and I had a long talk. I asked her from which state she was, recognizing her obvious American accent when speaking Dutch, but she said she was born and raised in Holland, and had not even been in America. Then where did the accent originate?
She claimed she came from Volendam, a fishing village in the west of Holland, that was why her speech sounded funny for someone from the east of the country like me. What was the woman thinking? That one doesn't hear the difference between a dialect and a foreign accent? Did she really think me that gullible? That was when the first red light in my head went off. But remember, I was desperate, running out of options, trusting my ex-husband and really wanting this to be something good. So I swallowed away my doubts. Not for the last time.
Joanna wanted to know about my drug history, my medical history, especially my psychiatric history. She wanted to know my financial background, my family's financial background, my religious background, and I had to sign some liability wavers, strictly routine of course, and than I was showed the house. There was an office, authorized personnel only, there was a communal living, with some old couches and chairs, and a fairly dirty kitchen annex dining-room.
Upstairs were the bedrooms; 2 to 4 persons of the same sex in a room. I was given a bed in a 2-person room. Luckily there was no other female to share with, so I had the luxury of my own bedroom.
Old mattresses, used by many people, and the laundry was changed just once a week, even for those in detox. The bedrooms didn't smell too good.... People kicking heroin tend to sweat a lot.
Down in the basement were the therapy-rooms and the famous sauna. It all looked rather primitive. Not that that was of the most importance, I could take that if they could cure me, but I did start wondering if it would be a good idea to take my two year old daughter to such a dirty and poorly maintained place. I also didn't see any other children in the house. It turned out that the promise about bringing my baby was another example of acceptable truth according to LRH. No way they were going to let me have my kid there, they just knew that I wouldn't have come if they said NO right away.
After the formalities were done I was offered a cup of tea in the living-room. To my surprise I met Jay there, a good mutual friend of Bob and me. He'd been at Narconon for some weeks now, he recruited Bob and Bob recruited me. One big happy family.....
Jay's mother came from a very wealthy family. She died of cancer about a year before this all happened, and, knowing about her sons drug-addiction, she put up this trust for him with a generous monthly allowance until he reached the age of 35 (He was about 25).
At 35 he would come in complete control of his inheritance, which amounted to a multimillion sum. His mother was afraid he'd spend it all on drugs, so she built in this safety, hoping that age would make him a little wiser. She, of course, never considered the lawyers of the Scientology church. More about that later.
To stay at Narconon you had to pay 100 guilders a day. Jay paid this for his friend Bob. My parents were willing to pay this for me. They were not rich people, but they had some savings and since I'm their only child, they thought it worthwhile. I made the arrangement with Joanna that I would pay for the first week myself, and that they wouldn't bother my parents about money before the second week. In the past I screwed up several rehab attempts during the first week because I couldn't stand the pain of cold turkey detox. I knew that, if I passed the first week, I'd probably complete the program. I didn't want my parents to be bothered about money before there was a fair chance of success. Joanna promised me that she wouldn't talk to my parents before day 7 and not without my knowledge.
The detox treatment consisted of massive doses of vitamins, weird communication trainings, and so called assists. I remember staring into each others eyes for hours, answering nonsense questions for hours, the so called bull-baiting, trying to upset the other over his/her weaknesses, the body-com, an assist to focus your thoughts on the here and now, went like this. While laying on a bed a volunteer put his/her hands on parts of your body, said “ feel my hands” and then you had to say thank you. And this went over and over again. Another was the nerve assist, which I personally found somewhat effective, but basically it was no more than an elaborate relaxing exercise.
Well, you can say that these things don't harm, but they don't really help either. What harmed were the absurd doses of vitamins and minerals without any medical supervision. Sure, you’d get a checkup before the sauna-treatment started, but the Church of Scientology doctor lived in Amsterdam, a two hour drive from Zutphen, and they didn't take you to a local doctor, not even in emergencies. I never saw this doctor.
That's why I never made it to the sauna, thank goodness. It is dangerous and scientifically unsound, it doesn't even make sense according to LHR's theories. Toxins, according to Hubbard, store in fat. By sweating you loose water, no fat, so what's the use? 5 hours of sauna daily plus strenuous physical excercise cause exhaustion and dehydration, even in people in great shape. Most drug-addicts are not. Combined with sleep deprivation, which comes naturally when going cold turkey, bad food, sessions of repeating the same nonsense for hours, badgering, bullying and bringing on fear (If you leave here you die, we are your last chance) this program is an example of classical brainwashing which the Chinese and the North Koreans couldn't improve.
After three days without sleep things became funny. I started wondering why we had to greet L. Ron Hubbard's portrait every morning, and why it was strictly forbidden to look into the course-material of those who were further along in the program. I started asking questions, first to myself, later to other people, and nobody came up with answers that made sense.
Another thing that bothered me was the money. There were about 30 pupils in the house. Private patients paid, at that time, 100 guilders per day. Part of the pupils were paid for by the Dutch Department of Corrections. According to Dutch law you can spend the last months of a prison sentence in a rehab-facility. The state paid 150 guilders a person a day. That totals about 3500 guilders a day. The groceries were about 200 guilders a day, of-course they had to pay mortgage on the house and the electricity bill, but 30 x 3500 makes a whopping monthly 105,000 Guilders a month (about 40,000 US$). Average per capita income in those days was about 1800 Gld. a month. Except for the director all of the staff volunteered, so hardly any costs were made on personnel.
Nevertheless we all had to write letters to businesspeople, in which we told about our addiction, our wish to become a productive member of society again and our poor widowed mother who couldn't pay for treatment. If they could be so kind to give something, completely tax-deductible, they would do so much good for the world..... Addresses came from the yellow pages, chamber of commerce, business-guides etc. Every story was a great big lie, copied from printed examples, but 30 people writing up to 100 letters every day make up for a lot of donations, even if only one percent would give something.
I asked where all the money went, why we had to eat cheap starchy food with chemical colorants and few proteins and vitamins in spite of all the ranting about food chemicals storing in our body fat. It sure is easier not to put them in in the first place, instead of spending hours in saunas to get rid of them. And why sit on smelly second hand furniture with burn-holes when there was such a stream of money coming in? No answers.
When in full withdrawal from opiates you have little control over your emotions. :oops: You laugh and cry at the most inappropriate moments. I started laughing during the daily LRH-greeting ritual and they became so angry, it scared me. They reacted as if I was painting pentagrams in a Baptist church. I didn't mean anything disrespectful, it was just the idea that struck me as being funny. I was taken to the office and three or four staff-members were browbeating me about being respectful of their religion. What religion? I was told they were religiously neutral, an independent and secular foundation that only used some of L.Ron's techniques.
Meanwhile they forbade people to read non-CoS religious books during treatment. They grudgingly allowed the Bible because it would cause too much adverse publicity to ban Bible-reading and the Department of Correction-inmates had the constitutional right to the Holy Scripture. But the Holy Books of other faiths were outright forbidden. Especially the books of the Bhagwan were scorned, probably because Rajneesj was the greatest contender on the souls-in-need market at the time.
I turned my head away to avoid the anger in their eyes and happened to see some faxes from the CoS HQ in Los Angeles. Couldn't really read them, but I could see they were about money. Meanwhile I was getting really sick from withdrawal, and still hadn't seen a doctor. Bob was there for almost two weeks by then, but he also hadn't seen a doctor yet.
Despite this lack of medical care he'd been through the worst of detox and had been in the sauna for several days. They say you get the sauna-treatment only after a thorough medical checkup, but only if the right doctor is at hand.
Rules are stricter now. Since the nineties several people died from heatstroke and exhaustion after the sauna, but in those days they were rather easy on the medical, in Holland at least. We didn't have wrongful damages and malpractice-trials and things like that in those days. By now we have. Suing is not just an American hobby anymore.
Anyway, the whole thing started to awake the innate sceptic in me. Too many things just didn't fit.
I saw too much that didn't fit. Suddenly I couldn't phone my parents anymore. There was a rule, they said, no phone-calls during the first week. I had phoned home all the days before, nobody said that I could not. That was, so they said, a BIG mistake of the staff-member that let me make those calls. They all did, and Bob was allowed to call me every day in his first week. Another rule that was invented on the spot. I found out that Joanna went to visit my parents, against our agreement. She denied it when she came back, but later that night told me that it was not a call about money, but just a social call, to explain family members about the program etcetera.
Funny thing was; she only went to parents that were supposed to pay the bill. Nobody visited Bob's parents, Jay paid for him. Jay's father, who was divorced from his mother long before she died and had no money of his own, never saw them. The solicitor who controlled his trust did get a visit. The parents of the jailbirds never saw anyone to explain the program, their offspring was provided for by the state. Only the milk-cows were visited. And milked dry.
I got so angry over this, that I couldn't sleep, couldn't stay in bed, had to do something.
A weird phenomenon with heroin-withdrawal is that, though you don't sleep, throw up, have cramps and sweat profusely, at some point in time everything becomes as clear as crystal. It's like a heightened form of perception, you hear, see, smell everything in your environment.
The mind also gets extremely clear, it starts making connections it would miss when at ease. This is a dangerous point in the process. Enlightenment can tip over to psychosis at any moment. It's hard to explain, but everything gets so real that it becomes unreal. This was the state I was in when things really got bizarre.
Experienced psychotherapists, secret-service agents and cult-converters recognize this state of mind. Here the patient gets crazy, converts or runs away, loudly screaming. I suppose I did the last (without the screaming part) because they made three big mistakes in handling me.
In hindsight I think, first of all, the handlers they used just weren't that good. The real good ones are put on the celebs and other big fish like heirs to family-fortunes. In their fixed worldview they couldn't see some average middle class junkie beat the tech. The thought just didn't come to their brainwashed minds.
The second mistake was their greed. They should have waited a little longer with putting the fishing rod in Bob's hand. He wasn't turned completely when I arrived; that gave both of us the chance to talk to a known, trusted, and not totally brainwashed person. Had they given Bob the time to turn, I would have been alone against the entire group. The odds would've gotten much worse for me and my freedom of thought.
Third mistake was the given opportunity to investigate on my own. Again these prejudices about drug-addicts that are only interested in drugs and their own short term gain. They just couldn’t fathom the idea of a heroin-user being capable to have independent thoughts.
And they should have given me the sense of love, family, belonging, purpose or whatever it is most people desperately try to find, instead of creating an atmosphere of paranoia, lies, greed and secrets. Any popular book about cults could have given them the basic techniques.
NEGATIVE: sleep deprivation, physical exhaustion, poor food, humiliation, imprinting by repeating absurd formulas. The fear of losing life and sanity if leaving the cult. General society is dangerous and out to get you, be it (depending on the cult) drug dealers, Satan, the CIA, the KGB, or the psychiatry-mafia, the world is a perilous place.
Thus separating you from your true family and friends, so you have nowhere to go.
POSITIVE: Creating a sense of trust, “you can tell us anything, we've been through the same, we understand." Creating a false sense of family, offering a chance of redemption, an opportunity to set things right, creating an atmosphere of warmth, love and kindness, once the first phase, the detox or the drilling or the introduction or whatever it is called, is over. WE LOVE YOU!!!
Main mistake in my case was their failure to see me as a person, they just saw the addict. And I've always been a strange one among addicts. For instance, I hated lies,and I never stole from friends and family. And even in my worst periods, I kept a keen interest in the world around me. It simply didn't occur to them that they really pissed me off (excuse my French...)
When everybody was in bed I went back to the living-room, and started reading the course-material of the higher level students. I read about the thetan in me, acceptable truth, which means that you are allowed to lie for a good cause, getting clear, and a lot of BS about engrams, auditing, LRH as Savior of Mankind through Scientology and all the mad rantings about how psychiatry caused every evil in the world. I literally got sick to my stomach. I knew there and then that I was trading my addiction for something far more insidious and far more dangerous; a mind-controlling cult.
The thing about the acceptability of lies shocked me, since I was being told that drug-users are liars, which is a bad habit, and I always had to be totally honest. To reach the desired level of honesty, one needed Narconon.
And there, in the book, it was written that lying was alright when it suited the cause of CoS.
WOW.
Even though I knew I was not supposed to, I tried the office-door. To my surprise it was unlocked. I took a closer look at the faxes lying on the desk, but they didn't make too much sense to me. Lots of lingo I didn't understand. But there was a steady stream of contact between Zutphen and LA-HQ, and money went from Narconon Holland to the Church of Scientology. Independent organization. Right. LIARS!
The next morning I talked to Bob and Jay about my doubts, and the feeling we were being brainwashed into the Scientology-church. Bob started getting his own doubts, but Jay was further along the line, and they've put a lot of energy into him. Big fish. I demanded a phone-call with my parents within the hour, else I would leave, and Bob would probably come with me. From that moment on Jay was effectively screened off from the both of us, and they tried to persuade Bob that I was a bad influence on his recovery. They tried to persuade me that it was a misunderstanding, that the phones where down and whatever, and that Bob was just wanting to make a prostitute out of me, like before.... (Sorry boys, but that simply never happened, just another assumption about a male and a female drug-addict living together), but I stood my ground. Either I'd speak to my parents and hear they did not pay my treatment yet, or I'd leave the place and go ask them myself.
They wouldn't budge, so I left. I suppose they finally realized that they couldn't stop me, and that, even if they could, I'd be a bad influence on the rest, so they let me go. Bob wanted to come with me, and since he nor his family had any money, they didn't try too hard to keep him. Damage control.
We left, I called my father at the nearest phone-booth and heard he did pay the 3000 guilders for one month treatment, and he wasn't too happy when I told him that his hard-earned cash went to the Church of Scientology. My skeptical streak didn't come from a stranger.
I asked him to come and get us, which he did. He picked us up at the station, we drove to Narconon, and I rang the door. Joanna's car was in the driveway, her coat was hanging in the hall, but the staff-member who opened said I was an unacceptable person now, only Joanna was allowed to talk to me, and she'd be gone all day. We could come back tomorrow for our things. I told him that we would be back in an hour, that I wanted both our belongings and the money my father payed. They could keep the money for the days I spent there, but the rest had to come back. Which was, of course, impossible, the money was in the safe, only Joanna had the key, she'd be gone all day, bla, bla.
At that moment I had another short flash of revelation. I realized that threatening with violence would make me end up in jail, threatening with the law wouldn't help because they have better lawyers and they know it, but there was one excellent option left; their fear of negative press-exposure.
I told them that I would give the whole story, everything we both experienced, saw and heard to a reporter of a magazine that was strongly anti-Scientology and had some good lawyers of its own. Their publisher had just won a lawsuit against the church about an article they published. Great timing.
I also told them I would invite this journalist and the local radio-station to witness how we we would not get our rightful belongings back.
The miracle happened. When we came back Joanna was there, with all the money minus the 500 for the days I stayed there, and all our possessions stood outside. Must have touched a sore spot...
I got money back from the CoS, which makes me one of a select few.. (Technically, they still scammed me for 100 guilders. I'd only stayed four days, not five. But what the ####) Bob asked to speak to Jay. But he was too scared, too intimidated, to come outside and talk to us.
That is the one thing I regret most, we couldn't save Jay. The last will his mother made up when she knew she was going to die, was contested by Scientology-lawyers. They won. The entire fortune was given at once to this poor insecure boy, who spent it all on Scientology-courses and was kicked out for drug abuse when the money was gone. Last thing I heard of him was that he was in prison for robbery, to finance his heroin-addiction. They took this gentle and vulnerable kid in, sucked him dry and left him to rot. They are just as bad as drug dealers. Maybe worse, the dope at least gives you some pleasure for your money, albeit only temporary.
And dealers are honest about their motivation. They don't pretend to save your soul while picking your bank-account clean.
I'm OK now, so is Bob, but it still makes me sad when I think of poor Jay. He never stood a chance.
Over the years at least two people have died at Narconon Netherlands, and it is still a registered charity, gifts are tax deductible, they put their fliers at youth counseling centers, centers for addiction advice, doctors offices etcetera. The Justice Department is still sending prisoners there. It is bizarre.
I really do think people get mixed up about the name. Narconon-Narcotics Anonymous-Alanon, it all sounds alike. Either that or they just don't want to hear, I don't know. It makes me angry that nothing has changed. The same scheme is still played and desperate people still lose. The lucky ones only lose their money. The unlucky ones lose their sanity, their freedom and sometimes even their life.
Victims are also volunteers that truly believe in what they are doing, and only want to help people. It is just that the organization is corrupt, so it doesn't work, no matter how well-motivated individual staff-members are. They are also victims, giving away their time, their energy and their caring spirit to make a couple of crooks rich beyond measure. Like the clients, they will only lose in the end. No retirement or disability plan for them when they get old or sick.
And in their Hollywood mansions or on their yachts Mister Miscavage and Mister Cruise and their minions and mistresses are having a great time, living their lives of luxury and laughing out loud about the stupid suckers who fall for their evil schemes. At least, that's what I think. But I'm just supposing. What do I know?
No matter how bad your situation is, no matter how addicted you are and to what substance, you don't need Narconon. There’s better options for treatment, both in Europe and in the Americas. I'm sure there are options in the rest of the world too. Fight your addiction, but beware of this dangerous scam. They are not there for you, just for your money.
Thanks for listening to my story, and for those whom it concerns: FIND HELP!
Sekh's story was originally posted on the Operation Clambake Message Board.
Have questions, comments, or information? Talk to us here in the Reaching for the Tipping Point forum: Narconon and related groups
Printable literature? A trifold flyer with information about Narconon is available here: http://www.reachingforthetippingpoint.net/NarcononFlyer-2010-06-11.pdf
submitted by BrianBizTexas to exscientology [link] [comments]

2020 Psychedelic Industry Insights Report

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[[email protected]](mailto:[email protected])
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development**:**
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to Drugs [link] [comments]

Vitamins and Minerals; Anti Aging; Physical fitness and nutrition (everything from endurance products to bodybuilders) Exogenous Ketones Affiliate Offers (HOT in the industry right now) No matter what area of health, performance or fitness your website covers, you’re guaranteed to find a product in our affiliate program that is right for your Top Health Vitamins-Pay-Per-Sale Affiliate Marketing Program How does our affiliate marketing work? Our affiliate marketing program is a performance-based marketing. Here, the Affiliates or Influencers earn a commission per unit sold of our products promoted on their website. Influencers. We welcome influencers to register as affiliates of our Naturally Vitamins Affiliate Commission Structure * 12% commission on all sales * 13.5% commission after $2,000 in sales * 15% commission after $5,000 in sales; For proven partners additional compensation may be available. Contact the affiliate team via Email to learn more. Program Restriction The myvitamins Affiliate programme is an easy way to earn revenue from your website, email list and/or social media. We use cookies to give you the best experience on our site. By continuing, you agree to our use of cookies Vitamins Letter Vitamins Vitamin A Vitamin B Vitamin C Vitamin D Vitamin E Vitamin K Multivitamins Women's Men's Kids' Vitamins 50+ Organic Vitamins Prenatal Packs Minerals Calcium Iron Magnesium If you want to become an affiliate and have your own website, join today and start earning commissions.

[index] [8497] [4047] [3679] [3600] [1466] [9006] [12586] [13243] [4731] [6181]